(SOLV) Solventum - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83444M1018

SOLV: Medical Supplies, Dental Products, Software Solutions, Purification

Solventum Corporation (NYSE:SOLV), a healthcare company, specializes in developing, manufacturing, and commercializing a diverse range of solutions to address critical customer and patient needs globally. Incorporated in 2023 and headquartered in Maplewood, Minnesota, Solventum operates across four key segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Each segment is strategically positioned to capitalize on growing market demands and technological advancements.

The Medsurg segment offers a comprehensive suite of products, including negative pressure wound therapy, advanced wound dressings, and medical technologies for OEMs, addressing the increasing demand for effective wound care solutions driven by an aging population. The Dental Solutions segment provides orthodontic products like clear aligners, aligning with the trend towards discreet orthodontic treatments. The Health Information Systems segment delivers digital solutions, riding the wave of healthcares digital transformation. The Purification and Filtration segment offers technologies addressing water and air quality concerns, a growing priority globally.

Solventum distributes its products through multiple channels, ensuring wide market reach and accessibility. The companys recent incorporation in 2023 positions it as a dynamic player in the healthcare industry, leveraging its diverse portfolio to drive growth and innovation.

Based on the moving averages, Solventums stock is currently in a short-term downtrend, trading below its SMA 20 and SMA 50. The SMA 200 at 68.28 may provide support. The ATR of 2.99 suggests moderate volatility, indicating possible price fluctuations within a range of 62.95 to 66.93 over the next three months. Considering the fundamental data, the forward P/E of 11.93 suggests potential undervaluation if earnings meet expectations. However, the P/B ratio of 3.87 indicates a premium, which could impact short-term gains. Overall, the stock may experience sideways movement with potential recovery if earnings exceed projections.

Additional Sources for SOLV Stock

SOLV Stock Overview

Market Cap in USD 11,683m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 2024-03-26

SOLV Stock Ratings

Growth Rating -7.50
Fundamental 15.2
Dividend Rating 0.0
Rel. Strength -0.01
Analysts 3.09/5
Fair Price Momentum 56.07 USD
Fair Price DCF 102.27 USD

SOLV Dividends

No Dividends Paid

SOLV Growth Ratios

Growth Correlation 3m -53.9%
Growth Correlation 12m 71.8%
Growth Correlation 5y 65.4%
CAGR 5y -15.96%
CAGR/Max DD 5y -0.40
Sharpe Ratio 12m -0.23
Alpha -6.42
Beta 0.511
Volatility 32.97%
Current Volume 1059.7k
Average Volume 20d 920.6k
What is the price of SOLV stocks?
As of May 01, 2025, the stock is trading at USD 66.12 with a total of 1,059,662 shares traded.
Over the past week, the price has changed by +0.33%, over one month by -13.05%, over three months by -10.72% and over the past year by +1.71%.
Is Solventum a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Solventum is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 15.17 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SOLV as of May 2025 is 56.07. This means that SOLV is currently overvalued and has a potential downside of -15.2%.
Is SOLV a buy, sell or hold?
Solventum has received a consensus analysts rating of 3.09. Therefor, it is recommend to hold SOLV.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 9
  • Sell: 1
  • Strong Sell: 0
What are the forecast for SOLV stock price target?
According to ValueRays Forecast Model, SOLV Solventum will be worth about 60.6 in May 2026. The stock is currently trading at 66.12. This means that the stock has a potential downside of -8.42%.
Issuer Forecast Upside
Wallstreet Target Price 80.9 22.3%
Analysts Target Price 80.9 22.3%
ValueRay Target Price 60.6 -8.4%